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Stability and localization of p53 is essential for its
tumor suppressor function. Ubiquitination by the E3
ubiquitin ligase Mdm2 is the major regulatory mech-
anism of p53, which induces p53 nuclear export and
degradation. However, it is unclear whether ubiquiti-
nated cytoplasmic p53 can be recycled. Here, we
report that USP10, a cytoplasmic ubiquitin-specific
protease, deubiquitinates p53, reversing Mdm2-
induced p53 nuclear export and degradation. After
DNA damage, USP10 is stabilized, and a fraction of
USP10 translocates to the nucleus to activate p53.
The translocation and stabilization of USP10 is regu-
lated by ATM -mediated phosphorylation of USP10
at Thr42 and Ser337. Finally, USP10 suppresses
tumor cell growth in cells with wild-type p53, with
USP10 expression downregulated in a high per-
centage of clear cell carcinomas, known to have
few p53 mutations. These findings reveal USP10 to
be a novel regulator of p53, providing an alternative
mechanism of p53 inhibition in cancers with wild-
type p53.
INTRODUCTION
p53 is an crucial tumor suppressor that is mutated in more than
50% of human cancers and whose major function is regulating
cell fate after cellular stress and repressing the propagation of
damaged cells (Lane, 1992; Riley et al., 2008; Vogelstein et al.,
2000). p53 functions as a transcription factor, and through its
target genes it regulates a variety of cellular functions, including
cellular senescence, energy metabolism, DNA repair, cell differ-
entiation, cell-cycle progression, and apoptosis.
p53 activity, expression, and localization are mainly regu-
lated by posttranslational modifications, such as phosphoryla-
tion, acetylation, and ubiquitination (Appella and Anderson,
2001). Mdm2 is an E3 ubiquitin ligase that plays a major
role in regulating p53. Mdm2-mediated ubiquitination of p53
induces p53 nuclear export and degradation (Boyd et al.,
2000; Freedman and Levine, 1998; Geyer et al., 2000; Haupt
et al., 1997; Honda et al., 1997; Kubbutat and Vousden,384 Cell 140, 384–396, February 5, 2010 ª2010 Elsevier Inc.1997; Stommel et al., 1999). Although nuclear export was
considered to be required for p53 degradation, later studies
demonstrated that p53 degradation could also occur in the
nucleus (Geyer et al., 2000; Lohrum et al., 2001; Shirangi
et al., 2002; Stommel and Wahl, 2004; Xirodimas et al.,
2001). The extent of p53 ubiquitination was suggested to deter-
mine p53 localization, with monoubiquitination inducing p53
nuclear export and polyubiquitination inducing nuclear degra-
dation of p53 (Li et al., 2003). Other E3 ubiquitin ligases have
also been shown to regulate p53 stability and/or localization,
such as COP1, Pirh2, ARF-BP1, MSL2, and Parc (Brooks and
Gu, 2006).
It is well documented that the ubiquitination of many proteins
can be reversed by deubiquitinases (DUBs). In the human pro-
teome, there are about 90 DUBs; however, the mechanisms
regulating p53 deubiquitination remain enigmatic. The ubiqui-
tin-specific protease HAUSP has been shown to deubiquitinate
p53, with overexpression of HAUSP resulting in p53 stabilization
(Li et al., 2002). However, depletion of HAUSP in cells does not
decrease p53 levels as predicted, but rather increases p53 levels
(Cummins et al., 2004), apparently because of HAUSP’s ability to
bind and deubiquitinate Mdm2 (Cummins et al., 2004; Li et al.,
2004). In fact, Mdm2 seems to be a better binding partner of
HAUSP than p53 (Hu et al., 2006; Sheng et al., 2006). Thus, it
would appear that the regulation of p53 by HAUSP is a rather
complex process. It is likely that Mdm2 is the preferred substrate
for HAUSP in unstressed cells, while genotoxic stress decreases
HAUSP’s binding to Mdm2/MdmX through ATM-dependent
phosphorylation (Meulmeester et al., 2005), tilting the balance
toward p53 stabilization (Brooks et al., 2007). In addition, HAUSP
mainly localizes in the nucleus (Everett et al., 1997; Song et al.,
2008), although a fraction of HAUSP has been shown to be
present in the cytoplasm and mitochondria. One pertinent
question arising from these studies pertains to the fate of ubiqui-
tinated cytoplasmic p53 and the pliability of this fate. It is
possible that there is a cytoplasmic counterpart of HAUSP
responsible for the deubiquitination of cytoplasmic p53, resulting
in p53 stabilization and translocation back to the nucleus. Here,
we identify USP10 as a p53 DUB. In unstressed cells, USP10
mainly localizes in the cytoplasm and regulates p53 homeo-
stasis. After DNA damage, USP10 also translocates to the
nucleus and contributes to p53 activation. These results reveal
an important missing piece in the regulation of p53 localization
and stability.
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Figure 1. USP10 Interacts with p53
(A–D) HCT116 p53+/+ and p53/ cell lysates were
subject to immunoprecipitation with control IgG,
anti-p53 (A and B), anti-USP10 (C), or anti-Mdm2
(D) antibodies. The immunoprecipitates were
then blotted with the indicated antibodies.
(E) Purified USP10 was incubated with GST or
GST-p53 coupled to GSH-Sepharose. Proteins
retained on Sepharose were then blotted with the
indicated antibodies.
(F) H1299 cells transfected with the indicated
constructs were lysed and lysates incubated
with GST or GST-p53-GSH-Sepharose. Proteins
retained on Sepharose were blotted with the indi-
cated antibodies.RESULTS
USP10 Interacts with and Stabilizes p53
By serendipity, we found that the ubiquitin-specific protease
USP10 interacts with p53. As shown in Figures 1A and 1B,
USP10 coimmunoprecipitated with p53 in HCT116 p53+/+ cells,
but not HCT116 p53/ cells. HAUSP also coimmunoprecipi-
tated with p53 (Figure 1A), as previously reported (Li et al.,
2002). Reciprocal immunoprecipitation with anti-USP10 also
brought down p53 in HCT116 p53+/+ and U2OS cells but not in
HCT116 p53/ cells (Figure 1C and data not shown). Unlike
HAUSP, USP10 did not interact with Mdm2 (Figure 1D). These
results suggest a specific interaction between USP10 and p53
in vivo. To determine whether the USP10-p53 interaction is
direct, we generated and purified recombinant USP10 and
p53. Purified His-USP10 was able to interact with GST-p53
under cell-free conditions, suggesting a direct interaction
between USP10 and p53 (Figure 1E). Mapping the region of
USP10 required for p53 binding revealed that the N-terminal
region (AA1-AA100) is critical for the interaction between
USP10 and p53 (Figure 1F). Furthermore, FLAG-USP10 (1-100)Cell 140, 384–396itself could interact with p53, suggesting
that AA1-100 of USP10 is both required
and sufficient for p53 interaction.
Since USP10 is an ubiquitin-specific
protease, it is possible that USP10 could
function to stabilize p53. Overexpression
of USP10 significantly increased the
levels of endogenous p53, with no effect
on p53 messenger RNA (mRNA) levels
(Figure 2A). We also observed increased
mRNA and protein levels of p21 and
Bax, two p53 target genes. On the other
hand, overexpression of USP10 deleted
of the p53 binding region (D1-100) did
not change the level of endogenous p53
compared to vector transfected cells
(Figure S1A available online). Consistent
with previous results (Li et al., 2002), over-
expression of HAUSP also increased
p53 levels (Figure 2A). To confirm the
role of USP10 in regulating p53 levels,we depleted USP10 using USP10-specific short hairpin RNA
(shRNA), andwe found that downregulation of USP10 decreased
p53 protein levels with no effect on p53mRNA levels (Figure 2B).
While the mRNA and protein levels of p21 and Bax were
also decreased, the decrease in p53 levels could be reversed
by the addition of proteasome inhibitor MG132, suggesting
that USP10 regulates p53 levels in a proteasome-dependent
manner. A second USP10 shRNA behaved similarly (Fig-
ure 2B). These results suggest that USP10 can upregulate p53
levels, most likely by deubiquitinating and consequently stabi-
lizing p53. To prove that USP10 affects p53 stability per se, we
treated control cells or cells stably expressing USP10 shRNA
with cycloheximide (CHX) and examined p53 stability. p53
stability was decreased in cells stably expressingUSP10 shRNA,
while reconstitution with shRNA-resistant USP10 restored
p53 stability (Figure 2C). These results confirmed the specificity
of our shRNA and also demonstrate that USP10 stabilizes p53
in cells.
HAUSP has also been shown to stabilize Mdm2 (Cummins
et al., 2004; Li et al., 2004); therefore, we examined how
USP10 would affect Mdm2 levels. Consistent with the previous, February 5, 2010 ª2010 Elsevier Inc. 385
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Figure 2. USP10 Stabilizes and Deubiquitinates p53
(A) HCT116 cells were transfected with the indicated constructs. Forty-eight hours later, proteins and mRNA were extracted and subjected to western blot or
QRT-PCR.
(B) HCT116 cells infected with lentivirus encoding the indicated shRNAs were left untreated or treated with MG132 for 4 hr, then proteins and mRNA were
extracted and subjected to western blot or QRT-PCR.
(A and B) Lower panel: quantification of p53, p21, or BAX transcript levels.
(C) HCT116 cells stably expressing control shRNA, USP10 shRNA, or USP10 shRNA together with shRNA-resistant USP10 were treated with cycloheximide
(0.1 mg/ml), and harvested at the indicated times. The left panels show immunoblots of p53 and USP10. (LE, long exposure; SE, short exposure.) Right panel:
quantification of the p53 protein levels relative to b-actin.
(A–C) Error bars represent the SEM of triplicate experiments.
(D) HCT116 p53+/+ and p53/ cells infected with lentivirus encoding the indicated shRNAs were lysed and lysates blotted with the indicated antibodies.
(E) HCT116 cells transfected with the indicated constructs were lysed and lysates blotted with the indicated antibodies.
(F and G) Regulation of p53 ubiquitination levels in vivo by USP10. HCT116 cells transfected with the indicated constructs (F) or stably expressing Ctrl or USP10
shRNA (G) were treated with MG132 for 4 hr before harvest. p53 was immunoprecipitated with anti-p53 polyclonal antibodies and immunoblotted with mono-
clonal anti-p53(DO-1) antibodies or anti-ub antibodies.
(H) Deubiquitination of p53 in vitro by USP10. Ubiquitinated p53 was incubated with purified USP10 or USP10CA in vitro, and then blotted with anti-p53
antibodies.
See also Figure S1.
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report, downregulation of HAUSP decreased Mdm2 levels,
which resulted in an increase in p53 levels (Figure 2D). Although
downregulation of USP10 also resulted in decreased Mdm2
levels, we believe this is secondary to a decrease in p53 levels.
Indeed, downregulation of USP10 did not affect Mdm2 levels
in p53-deficient cells (Figure 2D and Figures S1B and S1C), while
downregulation of HAUSP still decreased Mdm2 levels in p53-
deficient cells. These results suggest that USP10 and HAUSP
have differing roles in p53 homeostasis.
USP10 Deubiquitinates p53
It is likely that USP10 functions to deubiquitinate p53 to coun-
teract the action of E3 ubiquitin ligases such as Mdm2. Indeed,
as shown in Figure 2E, although overexpression of Mdm2
significantly induced the degradation of p53, coexpression of
USP10 effectively rescued p53 from Mdm2-induced degrada-
tion. We next examined whether USP10 regulates the levels
of p53 ubiquitination in cells. So that p53 ubiquitination could
be observed, the proteasome inhibitor MG132 was used in
Figures 2F and 2G. As shown in Figure 2F, Mdm2 induced
the ubiquitination of p53; however, p53 ubiquitination was
significantly diminished by coexpression of USP10 or HAUSP.
On the other hand, USP10C488A (USP10CA), the catalytic-
inactive USP10 mutant with a mutation at the core enzymatic
domain (Soncini et al., 2001), lost the ability to reverse p53
ubiquitination induced by Mdm2 (Figure 2F and Figure S1D).
Conversely, downregulation of USP10 increased p53 ubiquiti-
nation (Figure 2G). These results suggest that USP10 negatively
regulates p53 ubiquitination in cells. In order to directly examine
the deubiquitination activity of USP10 toward p53, we utilized
a cell-free system. We purified USP10 and USP10CA from
bacteria, as well as ubiquitinated p53 from cells expressing
FLAG-p53, pCMV-Mdm2, and HA-ub. We then incubated
USP10 and ubiquitinated p53 in a cell-free system. As shown
in Figure 2H, purified WT USP10, but not catalytically inactive
USP10, effectively deubiquitinated p53 in vitro. These results
demonstrate that USP10 deubiquitinates p53 both in vitro
and in vivo.
USP10 Localizes in the Cytoplasm and Counteracts
Mdm2 Action
Previous studies suggest that ubiquitination of p53 by Mdm2
could induce p53 translocation from nucleus to cytoplasm
(Boyd et al., 2000; Geyer et al., 2000; Li et al., 2003; Stommel
et al., 1999). In addition, the cytoplasmic ubiquitin ligase Parc
can ubiquitinate p53 and trap p53 in the cytoplasm (Nikolaev
et al., 2003). However, it is not clear whether cytoplasmic p53
can be deubiquitinated and returned to the nucleus. The majority
of HAUSP is localized in the nucleus (Marchenko andMoll, 2007;
Song et al., 2008); USP10, however, is predominantly localized
to the cytoplasm in both p53-proficient and p53-deficient cells
(Figure 3A and Figure S2A). We also confirmed the localization
of HAUSP and USP10 by cellular fractionation. As shown in
Figure S2B, HAUSP is predominantly localized in the nucleus,
while USP10 is localized in the cytoplasm. This led us to
hypothesize that USP10 is the cytoplasmic p53 deubiquitinase
that reverses Mdm2-induced nuclear export of p53. To test
this, we performed immunofluorescence assays to detect thesubcellular localization of p53. In control cells, p53 was readily
detected in the nucleus. As previously demonstrated (Boyd
et al., 2000; Geyer et al., 2000; Li et al., 2003; Stommel et al.,
1999), in cells transfected with Mdm2, we observed nuclear
export of p53 (Figure 3B). Coexpression of WT USP10 with
Mdm2 reversed Mdm2-induced cytoplasmic translocation of
p53. These results suggest that USP10 counteracts Mdm2’s
action and induce p53 translocation from the cytoplasm
back to the nucleus. To confirm this result, we performed cell
fractionation experiments and found that expression of Mdm2
induced ubiquitination and nuclear export of p53 (Figure 3C).
The nuclear export of p53 was reversed by USP10 coexpression
or LMB treatment. Therefore, a balance between USP10 and
Mdm2 could determine p53 localization. If so, downregulation
of USP10 could have similar effect to Mdm2 overexpression.
Consistent with our prediction, downregulation of USP10 itself
induced nuclear export of endogenous p53 (Figure 3D), which
could be blocked by LMB. Similar results were obtained with
a second USP10 shRNA (Figure 3D). Furthermore, downregula-
tion of USP10 increased the ubiquitination of p53 in the cyto-
plasm, but not in the nucleus (Figure 3E). Although p53 could
be downregulated by the ubiquitin pathway in both cytoplasm
and nucleus (Figure S2C), the stability of cytoplasmic p53, but
not that of nuclear p53, was decreased in cells depleted of
USP10 (Figure S2D). Overall, our results from Figures 2 and 3
establish USP10 as the cytoplasmic deubiquitinase for p53
and the important role of USP10 in regulating homeostasis of
p53 in cells.
USP10 Regulates p53 Function
USP10’s effects on p53 stabilization and nuclear import raised
the possibility that USP10 regulates p53-dependent transcrip-
tional activity, cell transformation, and apoptosis. As shown in
Figure 4A, overexpression ofWTUSP10 increased p21 promoter
activity in HCT116 p53+/+ cells but not in HCT116 p53/ cells. In
contrast, catalytically inactive USP10 (USP10 CA) or USP10
deletion mutant that was deleted of the p53 binding region
(D1–100) could not affect p53 transcriptional activity. Stable
knockdown of USP10 by shRNA inhibited p21 promoter activity
in HCT116 p53+/+ cells but had little effect in HCT116 p53/
cells (Figure 4B). These results suggest that USP10 regulates
p53-dependent transcription activity. Furthermore, we tested
whether USP10 directly affects p53-dependent apoptosis. As
shown in Figure 4C, overexpression of p53 induced apoptosis,
while Mdm2 strongly reduced p53-dependent apoptosis.
However, coexpression of USP10 or HAUSP, but not USP10
CA or USP10D1-100, significantly reversed the inhibitory effect
of Mdm2 on p53-mediated apoptosis. We further investigated
how USP10 affects cell proliferation. As shown in Figure 4D,
downregulation of USP10 increased cancer cell proliferation in
p53+/+ cells, while USP10 expression levels have no apparent
effect on proliferation in cells lacking p53. A similar effect was
observed when cancer cells were culture in soft agar
(Figure 4E). On the other hand, reconstitution of USP10 in cells
with USP10 downregulation inhibited cancer cell proliferation
(Figure 4E), suggesting that the effect of USP10 knockdown is
specific. Overall, these results suggest that USP10 potentiates
p53 function in cells.Cell 140, 384–396, February 5, 2010 ª2010 Elsevier Inc. 387
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Figure 3. Regulation of Subcellular Localization of p53 by USP10
(A) Subcellular localization of USP10 and HAUSP. U2OS cells were fixed and stained as indicated. Scale bars represent 10 mm.
(B) HCT116 cells transfected with the indicated constructs were treated with MG132 for 4 hr, then fixed and stained as indicated. Scale bars represent 10 mm.
(C) HCT116 cells transfected with the indicated constructs were treated with MG132 and then left untreated or treated with 25 ng/ml leptomycin B (LMB). After
4 hr, cells were harvested and fractionated as described in the Experimental Procedures. Cellular fractions were then blotted with the indicated antibodies.
(C, cytoplasmic; N, nuclear.) A cytoplasmic marker protein, Tubulin, and a nuclear marker protein, MAX, were used as controls to confirm the quality of fractions.
LE, long exposure; SE, short exposure.
(D) HCT116 cells infected with lentivirus encoding the indicated shRNAs were treated with MG132 and then left untreated or treated with LMB. An additional 4 hr
later, cells were fixed and stained as indicated. Scale bars represent 10 mm.
(B and D) Lower and right panels: quantification of cells with different p53 subcellular localization. Nuc, Nucleus only; Cyto + Nuc, both cytoplasm and nucleus.
The data represent the average of three experiments, and 150 cells were monitored in each experiment.
(E) HCT116 cells stably expressing the indicated shRNAs were treated with MG132 for 4 hr. Then cells were harvested and fractionated, and cytoplasmic or
nuclear p53 was immunoprecipitated with anti-p53 polyclonal antibodies and immunoblotted with monoclonal anti-p53 (DO-1) antibodies.
See also Figure S2.
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Figure 4. Effects of USP10 on p53-Mediated
Transcriptional Activity, Cell Growth
Repression, and Apoptosis
(A) p53 reporter constructs for the p21 promoter
were cotransfected with the indicated constructs
into HCT116 p53+/+ and HCT116 p53/ cells.
Reporter activity was then determined as
described in the Experimental Procedures.
(B) p53 reporter assay was performed in HCT116
p53+/+ and HCT116 p53/ cells stably expressing
the indicated shRNAs.
(C) H1299 cells were transfected with the indicated
constructs. Forty-eight hours later, apoptotic cells
were determined.
(D) HCT116 p53+/+ and HCT116 p53/ cells stably
expressing the indicated shRNAs were plated and
cell proliferation was then quantified at the indi-
cated times.
(E) Soft agar colony-formation assay was
performed with HCT116 p53+/+ and HCT116
p53/ cells stably expressing control shRNA,
USP10shRNA, or USP10shRNA together with
shRNA-resistant USP10. Right panel: quantifica-
tion of colonies formed in soft agar. Scale bars
represent 400 mm.
Error bars represent the SEM of triplicate experi-
ments. **p < 0.01 two tailed student’s t test.USP10 Is Upregulated and Translocates to the Nucleus
after DNA Damage and Regulates p53-Dependent DNA
Damage Response
We have shown that USP10 can regulate p53 homeostasis in
unstressed cells. Since p53 plays an important role in DNA
damage response and becomes stabilized after DNA damage,
we next asked whether USP10 is important for p53 stabilization
and activation after DNA damage. Interestingly, downregulation
of USP10 significantly decreased p53 stabilization and the
expression of p53 target genes p21 and Bax after DNA damage
(Figure 5A). We also observed increased p53 ubiquitination
in cells depleted of USP10 after DNA damage (Figure S3A).
Upstream signaling events such as ATM phosphorylation were
unaffected by USP10 downregulation (Figure S3B). These
results suggest that USP10 regulates p53 stabilization after
DNA damage. We also observed that the expression of USP10
itself was increased after DNA damage. These results are
rather surprising, since most DNA damage signaling is thought
to occur in the nucleus. How is it that USP10, a largely cyto-
plasmic protein, affects p53 stabilization during DNA damage
response? It is possible that p53 is still actively exported out of
the nucleus and gets degraded in the cytoplasm during DNA
damage response. Alternatively, USP10 could translocate intoCell 140, 384–396the nucleus to participate in DNA damage
response. Indeed, we found by immuno-
fluorescence that a portion of USP10
appears to relocalize to the nucleus after
DNA damage (Figure 5B). LMB treatment
also induced USP10 nuclear localization,
suggesting that USP10 is actively ex-
ported out of the nuclear in unstressedcells. The translocation of USP10 could be blocked by the
ATM inhibitor Ku55933 (Hickson et al., 2004), suggesting that
USP10 translocation after DNA damage is ATM dependent. To
confirm the translocation of USP10, we performed cell fraction-
ation assays. As shown in Figure 5C, increased amounts of
USP10 were detected in the nucleus after DNA damage, and
this translocation of USP10 also occurred in p53 null cells, sug-
gesting the translocation of USP10 is p53 independent.
To confirm that translocated USP10 is functional, we fraction-
ated cells treated with ionizing radiation (IR). As shown in Figures
S3C and S3D, nuclear USP10 is still able to bind and deubiquiti-
nate p53. These results imply that USP10 translocation could
contribute to p53 activation in the nucleus. To test this notion,
we further examined whether USP10 is required for p53-depen-
dent function during DNA damage response. As shown in
Figure 5D and Figure S3E, downregulation of USP10 inhibited
IR-induced apoptosis in HCT116 p53+/+ cells. The IR-induced
apoptosis in HCT116 p53/ cells was attenuated; however,
downregulation of USP10 did not have any further effect.
Furthermore, knockdown of USP10 in HCT116 p53+/+ cells
resulted in defective DNAdamage-inducedG1 arrest (Figure 5E).
These results are consistent with decreased Bax and p21
expression in cells with USP10 downregulation (Figure 5A) and, February 5, 2010 ª2010 Elsevier Inc. 389
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Figure 5. USP10 Translocates into the
Nucleus and Regulates p53 Activity after
DNA Damage
(A) HCT116 cells stably expressing the indicated
shRNAs were irradiated (10Gy) and harvested at
indicated times, and cell lysates were then blotted
with the indicated antibodies.
(B) HCT116 cells were left untreated, treated with
10Gy radiation, with LMB, with both, or treated
with Ku55933 (ATM-specific inhibitor) for 1 hr
then irradiated. An additional 1 hr later, cells were
fixed and stained as indicated. Scale bars repre-
sent 10 mm.
(C) HCT116 p53+/+ or HCT116 p53/ cells were
irradiated (10Gy) or left untreated. After 1 hr, cells
were harvested and fractionated. Cellular fractions
were then blotted with the indicated antibodies.
(D) HCT116 p53+/+ or p53/ cells stably express-
ing the indicated shRNAs were left untreated or
treated with 10Gy radiation. After 48 hr, apoptotic
cells were determined. Error bar represent the
SEM of triplicate experiments. **p < 0.01 two tailed
student’s t test.
(E) The same cells in (D) were treated with 10Gy
radiation, then harvested at the indicated times.
Cell-cycle profiles were determined by FACS.
See also Figure S3.suggest that USP10 is required for p53 activation after DNA
damage.
USP10 Phosphorylation by ATM Is Required for Its
Stabilization and Translocation after DNA Damage
We next sought to determine the molecular mechanisms that
regulate USP10 upregulation and translocation. Initial experi-
ments indicated that the upregulation of USP10 occurs both in
p53-WT and p53 null cells (Figure S3F). Furthermore, unlike
p21, the upregulation of USP10 occurred without any change
in USP10 mRNA (Figure 6A). These results suggest that DNA
damage induced upregulation of USP10 is not regulated at the
transcriptional level and might be regulated at the posttransla-
tional levels. To examine whether USP10 protein becomes stabi-390 Cell 140, 384–396, February 5, 2010 ª2010 Elsevier Inc.lized, we irradiated and then treated cells
with CHX. As shown in Figure 6B, USP10
accumulation in irradiated cells is due to
increased stability.
Phosphorylation is a major posttransla-
tional modification of the DNA damage
response pathway and has been shown
to enhance protein stability and activity.
For example, p53 is phosphorylated at
Ser20 by the checkpoint kinase Chk2
after IR, which results in p53’s dissocia-
tion fromMdm2 and its subsequent stabi-
lization (Chehab et al., 2000; Hirao et al.,
2000; Shieh et al., 2000). Therefore, we
examined whether USP10 stabilization is
regulated by ATM. As shown in Figures
S4A and S4B, USP10 is less stable inATM-deficient cells, suggesting that USP10 stability is regulated
by ATM. We also observed DNA damage-inducible interaction
between USP10 and ATM (Figure S4C). These results implying
that USP10 might be phosphorylated by ATM after DNA
damage, which results in USP10 stabilization and relocalization.
Indeed, after various genotoxic stresses (IR, UV, or etoposide
treatment), USP10 became phosphorylated at SQ/TQ motifs
(Figure 6C and Figure S4D; USP10 protein levels were equalized
to specifically examine USP10 phosphorylation in experiments
of Figures 6C, 6D, 6G, and 6H and Figures S4D, S4F, and
S4G), which are consensus phosphorylation sites for PI3-kinase
like kinases (PIKKs), such as ATM, ATR, and DNA-PK (Abraham,
2001). Both pan-PIKK inhibitor caffeine and ATM inhibitor
Ku55933 inhibited USP10 phosphorylation after DNA damage
(Figure 6C). These results suggest that ATM regulates USP10
phosphorylation after DNA damage. We further confirmed the
role of ATM in USP10 phosphorylation using ATM+/+ or ATM/
cells. As shown in Figure 6D, USP10 failed to be phosphorylated
at the SQ/TQ motifs in ATM/ cells. Furthermore, USP10 levels
did not increase after DNA damage in ATM/ cells (Figure 6E).
These results suggest that USP10 is phosphorylated by ATM
after DNA damage, which contributes to its stabilization.
We next set out to determine the ATM phosphorylation sites of
USP10. ATM specifically phosphorylates SQ/TQmotifs, of which
there are two candidate sites in USP10: T42Q and S337Q. We
found that mutation at either T42 or S337 partially affects
USP10 stabilization and mutating both T42 and S337 (TS/AA)
abolished USP10 stabilization after DNA damage (Figure 6F
and Figure S4E). Mutation of both T42 and S337 (TS/AA) also
abolished USP10 phosphorylation by ATM (Figure 6G). To
confirm these results, we generated phosphorylation site-
specific antibodies against p-T42 and p-S337. As shown in
Figure 6H and Figures S4F and S4G, both T42 and S337 sites
were phosphorylated after DNA damage, and Ku55933 or T42/
S337 mutations inhibited USP10 phosphorylation after DNA
damage. These results suggest that T42/S337 are physiological
sites for ATM in vivo. In addition, the TS/AA mutant failed to
translocate into the nucleus after DNA damage (Figure 6I and
Figure S4H). On the other hand, a phospho-mimetic mutant of
USP10-T42E/S337D (TS/ED) translocated to the nucleus in the
absence of genotoxic stress (Figure 6I and Figure S4I), suggest-
ing that phosphorylation of USP10 by ATM is sufficient to induce
USP10 translocation. These results suggest that ATM-mediated
phosphorylation of USP10 is required for USP10 translocation
and stabilization.
We further examined the functional significance of USP10
phosphorylation by ATM. HCT116 cells stably expressing
USP10 shRNA were reconstituted with shRNA-resistant WT
USP10 or USP10 TS/AA. As shown in Figure 6J, cells express-
ing the USP10 TS/AA mutant show defective p53 stabilization
and poor induction of Bax and p21 after DNA damage. In
addition, reconstitution with WT USP10, but not the USP10
phospho mutant, restored DNA damage-induced apoptosis
(Figure 6K). The defect of the TS/AA mutant is not due to an
intrinsic defect in its ability to bind and deubiquitinate p53,
since the TS/AA mutant is still able to bind p53 (Figures S4J–
S4M) and can deubiquitinate p53 (Figure S4N). Overexpression
of the TS/AA mutant in cells is also able to reverse Mdm2-
induced p53 ubiquitination (Figure S4O). Therefore, failure to
translocate to the nucleus and be stabilized is the likely under-
lying mechanism for USP10 TS/AA’s failure to activate p53 in
response to DNA damage. Overall, our results establish the
important role of USP10 phosphorylation in p53 activation after
DNA damage.
USP10 Is Downregulated in Renal Cell Carcinoma
Since p53 is an important tumor suppressor that regulates cell
proliferation and USP10 potentiates p53 function by deubiquiti-
nating p53, it is possible that USP10 also acts as a tumor
suppressor. Our results shown in Figures 4D and 4E demon-
strate USP10’s ability to inhibit cancer cell proliferation and
lend support to the hypothesis that USP10 functions as a tumorsuppressor in vivo. To further test this hypothesis, we examined
the expression of USP10 in a panel of renal cell carcinoma (RCC)
cell lines. We chose RCC to study USP10 expression because
a very low percentage of RCC cases has been found to have
p53 mutations (Soussi et al. [2000] and the IARC p53 Database
[http://www-p53.iarc.fr/]). Given the important function of p53
in tumor suppression, it is likely that the p53 pathway is compro-
mised in RCC through other mechanisms, such as the downre-
gulation of USP10. Indeed, we found that USP10 expression is
significantly decreased in several RCC cell lines, including
A498, Caki-1, and Caki-2 cells, all of which contain WT p53
(Figure 7A). p53 expression was also lower in these cells than
that of normal renal cells. This decreased p53 expression is
not due to decreased p53 transcript (Figure 7A) and could be
increased by MG132 treatment (Figure S5A), suggesting that
p53 levels are regulated by the proteasome pathway in these
cells. Interestingly, in RCC cell lines with mutant p53 (769-P
and 786-O), USP10 as well as p53 levels were increased
(Figure 7A). USP10 levels were also decreased in majority of
fresh frozen RCC tissues compared to corresponding normal
tissues (Figure 7B). The RCC samples with USP10 downregula-
tion all contain WT p53 gene (T1–T9), although p53 levels were
decreased. The decreased p53 expression is not due to
Mdm2/Mdmx overexpression (Figure S5B). The Arf gene also
does not show mutations in these tumor samples (data not
shown). These results suggest that downregulation of USP10
might be an alternative way to suppress p53 activity in RCC.
Interestingly, USP10 is overexpressed in some RCC tissues,
and these tissues also contain mutant p53 (T10 and T11). These
results suggest that increased USP10 level in mutant p53 back-
ground might be beneficial to tumor growth. We further exam-
ined the expression of USP10 using RCC tissue microarray.
The specificity of the USP10 antibody for immunohistochemistry
was confirmed in Figure S5C. We scored the staining of USP10
from 0–3 and arbitrarily designated staining score 0–1 as nega-
tive and 2–3 as positive. Representative staining and scores
were shown in Figure 7C. To confirm these results, we also
used another USP10 antibody (Figure S5D). Strikingly, both
two USP10 antibodies staining showed that close to 90% of
clear cell carcinoma show negative staining of USP10. p53 stain-
ing was mostly negative in clear cell carcinoma (Figure S5D).
About 50% of chromophobe and 20% of papillary RCC show
negative USP10 staining (Figure 7C and Figure S5D). These
results suggest that USP10 is downregulated in RCC cases,
especially clear cell carcinoma.
To confirm the role of USP10 in tumor suppression, we recon-
stituted USP10 in RCC cells with USP10 downregulation and
examined tumor cell growth using soft agar assay. Reconstitu-
tion of USP10 in CAKI-1 and CAKI-2 (WT p53 cell lines) restored
p53 expression and increased p21 and BAX expression
(Figure S5E). Furthermore, colony formation and cell proliferation
were inhibited with USP10 reconstitution (Figure 7D and data not
shown). Downregulation of p53 abolished the inhibitory effect of
USP10 on tumor growth (Figure 7D and data not shown), con-
firming that USP10 inhibits cancer cell growth by stabilizing p53.
USP10 is overexpressed in RCC cell lines and tissues with
mutant p53, correlating with increased p53 levels (Figures 7A
and 7B). This is consistent with the observation that mutantCell 140, 384–396, February 5, 2010 ª2010 Elsevier Inc. 391
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Figure 6. USP10 Phosphorylation by ATM Regulates USP10 Stabilization, Rranslocation, and p53 Activation after DNA Damage
(A) HCT116 cells were irradiated (10Gy) and harvested at the indicated times. Protein and mRNA were extracted and analyzed by western blot or QRT-PCR,
respectively.
(B) HCT116 cells left untreated or irradiated were treated with CHX and harvested at the indicated times. Cell lysates were then blotted with the indicated anti-
bodies.
(C) HCT116 cells transfected with FLAG-USP10 were pretreated with DMSO, 25mMKu55933, or 3 mM caffeine. After 2 hr incubation, cells were left untreated or
irradiated (10Gy). After an additional 1 hr, FLAG-USP10 was immunoprecipitated with anti-FLAG antibody and immunoblotted with phospho-SQ/TQ (pSQ/TQ)
antibody.
(D) ATM +/+ or ATM / cells were irradiated (10 Gy) or left untreated. After 1 hr, USP10 was immunoprecipitated and immunoblot with the indicated antibodies.
(E) ATM+/+ and ATM/ cells were irradiated (10Gy) and harvested at the indicated times and lysates blotted with the indicated antibodies.
(F) HCT116 cells stably expressing USP10 shRNA were reconstituted with shRNA-resistant FLAG-USP10 WT, T42A, S337A, or TS/AA (T42A and S337A double
mutant). Cells were irradiated (10Gy) and harvested at the indicated times and lysates blotted with the indicated antibodies.
(G) HCT116 cells stably expressing USP10 shRNA were reconstituted with shRNA-resistant FLAG-USP10 WT or TS/AA. Cells were left untreated or irradiated
(10Gy), and USP10 phosphorylation was examined with pSQ/TQ antibody.
(H) HCT116 cells were left untreated or treated with Ku55933 for 2 hr then irradiated. The phosphorylation of USP10 was examined by site-specific phospho
antibodies: p-T42 and p-S337.
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p53 is often overexpressed in many cancers. To confirm that the
mutant p53 is still subjected to Mdm2 and USP10 regulation, we
investigated mutant p53 ubiquitination. As shown in Figure S5F,
expression of Mdm2 enhanced p53 ubiquitination in 786O cells,
suggesting that Mdm2 targets mutant p53 for degradation. This
is consistent with a recent interesting report that mutant p53
level is regulated by Mdm2 (Terzian et al., 2008). Coexpression
of USP10 together withMdm2 decreasedmutant p53 ubiquitina-
tion (Figure S5F), while downregulation of USP10 increased
mutant p53 ubiquitination (Figure S5G), suggesting that USP10
also regulates mutant p53 ubiquitination. Furthermore, expres-
sion of USP10 increased mutant p53 stability (Figure S5H), while
downregulation of USP10 decreased mutant p53 stability
(Figure S5I), suggesting that USP10 regulates mutant p53
stability.
Since mutant p53 is often dominant and displays gain of func-
tion, increased p53 levels could be advantageous to cancer. We
reasoned that in contrast to cells withWT p53, increased expres-
sion of USP10 in mutant p53 background would be beneficial to
cancer cell proliferation. Indeed, increased expression of USP10
in 786-O cells, which contain mutant p53, resulted in increased
colony formation and cell proliferation (Figure 7E and data not
shown), which could be reversed by p53 depletion. Although
the levels of mutant p53 increased in cells ectopically expressing
USP10, the expression of normal p53 target genes was not
affected (Figure S5E). These results suggest that p53 is not func-
tioning normally and has oncogenic gain-of-function in 786O
cells. Conversely, downregulation of USP10 inhibited cell prolif-
eration (Figure 7E and data not shown). Again, mutant p53 level
was decreased when USP10 was downregulated, but the
expression of p21 and Bax was not affected (Figure S5J). These
results suggest that USP10 regulates p53 and cancer cell prolif-
eration in a context-dependent manner. In cancer cells with WT
p53, USP10 acts as a tumor suppressor, and activating USP10
might be a sensible therapeutic strategy. On the other hand, in
cancer cells with mutant p53, USP10 could promote cancer
cell growth, and inhibition of USP10 is called for.
Overall, our studies suggest that USP10 is a deubiquitinase for
p53. In unstressed cells, USP10 localizes in the cytoplasm and
regulates p53 homeostasis. After DNA damage, a fraction of
USP10 translocates to the nucleus and contributes to p53 acti-
vation (Figure 7F). USP10, through its regulation of p53, appears
to play an important role in cancer biology.
DISCUSSION
The current study identifies USP10 as a p53 deubiquitinase.
Unlike HAUSP, a previously identified deubiquitinase for p53
and Mdm2, USP10 only interacts with p53, not Mdm2. In addi-
tion, while the majority of HAUSP localizes in the nucleus,
USP10 seems to be predominantly cytoplasmic in unstressed(I) Cells as in (G) and cells expressing a phosphomimetic mutant of USP10-T42E/
harvested and fractionated. Fractions were then blotted with the indicated antib
(J) Cells as in (G) were irradiated (10Gy) and harvested at the indicated times, ce
(K) Cells as in (G) were left untreated or irradiated, and apoptotic cells were determ
two tailed student’s t test.
See also Figure S4.cells. Although ubiquitination of p53 has long been known to
induce its nuclear export, whether or not the exported p53 could
be recycled back to the nucleus was unknown. Here, we demon-
strate that USP10 is able to reverseMdm2-mediated p53 nuclear
export. This is the first time that a deubiquitinase has been
demonstrated to deubiquitinate cytoplasmic p53. Therefore,
Mdm2 induced p53 ubiquitination could be counteracted at
two locations: either by HAUSP in the nucleus or USP10 in the
cytoplasm.
We also show that after genotoxic stress, a fraction of USP10
translocates to the nucleus, and this translocation is required for
the stabilization and activation of p53.Mechanistically, the phos-
phorylation of Thr42 and Ser337 of USP10 by ATM is required for
USP10 translocation and stabilization. Currently, we do not
know how the phosphorylation of USP10 affects its stability
and localization. Neither do we know the relationship between
USP10 translocation and stabilization. USP10 contains a poten-
tial nuclear localization sequence (NLS) and several Leu/Ile rich
regions, which are potential nuclear export signals (NES). Treat-
ment of cells with LMB induced USP10 accumulation in the
nucleus, suggesting that USP10 is actively exported out of
nucleus in unstressed cells. It is possible that USP10 phosphor-
ylation by ATM hinders USP10 nuclear export and shields it
from degradation in the cytoplasm. We will examine this further
in the future.
There are several mechanisms have been shown to stabilize
and activate p53 after DNA damage. The phosphorylation of
p53 by ATM or Chk2 has been shown to inhibit Mdm2 binding
(Banin et al., 1998; Chehab et al., 2000; Shieh et al., 1997,
2000). Furthermore, ATM-dependent phosphorylation of Mdm2
and Mdmx could destabilize these proteins and compromise
their activity (Khosravi et al., 1999; Maya et al., 2001; Meul-
meester et al., 2005; Pereg et al., 2005; Stommel and Wahl,
2004). Our results that USP10 is important for p53 stabilization
and activation after DNA damage provide another regulatory
route. Our results suggest that p53 is still ubiquitinated by
residual Mdm2/Mdmx activity after DNA damage (Figure S3A),
and the nuclear translocation of USP10 could further boost
p53 activation. Since p53 is such an important factor in the deter-
mination of cell fate, such multiple regulatory mechanisms
ensure optimal stress response.
Through its action toward p53, USP10 could function as
a tumor suppressor. We show downregulation of USP10 in
a high percentage of renal cell carcinoma samples. Furthermore,
we provide evidence that USP10 inhibits cancer cell proliferation
in cells with WT p53. These results suggest that USP10 could
suppress tumorigenesis. Since very low percentage of RCC
cases are found to have p53 mutations (Soussi et al. [2000] and
the IARC p53 Database [http://www-p53.iarc.fr/]), decreased
expression of USP10 could be another mechanism to inhibit
p53 function in RCC.S337D (TS/ED), lower panel, were irradiated (10Gy) or left untreated, and then
odies.
ll lysates were blotted with the indicated antibodies.
ined 48 hr later. Error bar represent the SEMof triplicate experiments. **p < 0.01
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Figure 7. USP10 Is Downregulated in Renal Cell Carcinoma
(A) Expression of USP10 and p53 in Human renal tubular epithelial cell line (HK-2) and renal cell carcinoma (RCC) cell lines. Right panel shows p53 transcript level
of HK-2 and RCC cells. Error bars represent the SEM of triplicate experiments.
(B) Eleven pairs of fresh frozen RCC tissues and corresponding normal tissues were lysed, and cell lysates were blotted with the indicated antibodies. (N, normal
tissue; T, tumor tissue.)
(C) Immunohistochemical staining of USP10 in normal renal tissues and renal cell carcinoma. Lower table: quantification of USP10-positive or USP10-negative
renal cell carcinoma cases. (ccRCC, clear cell renal cell carcinoma.)
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Paradoxically, USP10 could promote cancer cell proliferation
in mutant p53 background. We found USP10 is overexpressed
in RCC cells with mutant p53. Recent papers also suggest that
increased USP10 expression in some breast cancer and glio-
blastoma samples (Deng et al., 2007; Grunda et al., 2006),
although it is not clear whether p53 is mutated in these samples.
One mystery in the p53 field of research is that mutant p53 is
usually overexpressed in tumor samples; however, the mecha-
nism responsible for this phenotype is not clear. Although it
was thought that mutant p53 is intrinsically stable, a recent paper
suggest that downregulation of Mdm2 might be one mechanism
(Terzian et al., 2008). In contrast to mice with WT p53 back-
ground, loss of the Mdm2 in mutant p53 background increases
p53 expression and promotes tumorigenesis. The explanation
is that mutant p53 has a gain of function, and loss of Mdm2
increases mutant p53 levels and further promotes tumor devel-
opment. Consistent with this study, we show that increased
USP10 expression in mutant p53 background increases p53
levels and promotes cancer cell proliferation, while downregula-
tion of USP10 inhibits cancer cell growth. Therefore, increased
expression of USP10 could be another mechanism responsi-
ble for increased mutant p53 expression in human cancers.
Future studies, for example generating USP10 knockout mice,
are needed to establish the physiological role of USP10 in
tumorigenesis.
EXPERIMENTAL PROCEDURES
Deubiquitination of p53 In Vivo and In Vitro
Ubiquitination of p53was detected as described previously (Li et al., 2002). For
the in vivo deubiquitination assay, transfected HCT116 cells were treated
for 4 hr with a proteasome inhibitor MG132 (50 mM) before being harvested.
The cell extracts were subjected to immunoprecipitation and western blot.
For preparation of ubiquitinated p53 as the substrate for the in vitro deubi-
quitination assay, HEK293 cells were transfected with both HA-UB and
FLAG-p53, or pCMV-Mdm2. After treatment as described above, ubiquiti-
nated p53 was purified from the cell extracts with anti-FLAG-affinity column
in FLAG-lysis buffer. After extensive washing with the FLAG-lysis buffer, the
proteins were eluted with FLAG-peptides (Sigma). The recombinant His-
USP10 and USP10CA were expressed in BL21 cells and purified with the
His-tag purification column (Novagen). For the in vitro deubiquitination assay,
ubiquitinated p53 protein was incubated with recombinant USP10 in a deubi-
quitination buffer for 2 hr at 37C.
Apoptosis Assay
Cells were washed with PBS and fixed in 4% paraformaldehyde at room
temperature and then stained with DAPI. The number of cells with nuclear
morphology typical of apoptosis were analyzed by fluorescence microscopy
and scored in at least 400 cells per sample by an analyst blinded to the sample
groups.
Colony and Soft Agar Colony-Formation Assays
The soft agar colony-formation assay was performed as described (Shim et al.,
1997). Cells were plated in 0.3% top agarose in 35 mm dishes and cultured
for 2 weeks. Colonies were counted at room temperature under a light
microscope.(D and E) Soft agar colony-formation assay was performed with CAKI-1 CAKI-2, o
tion of colonies formed in soft agar. Error bars represent the SEM of triplicate ex
(F) The working model of p53 regulation by USP10.
See also Figure S5.Tissue Microarray
The tissue arrays of Kidney cancer samples were purchased from US Biomax
(KD 2083, KD991t, KD804, KD241, and KD208t). Immunohistochemical stain-
ing of USP10 (dilution 1:500) was carried out with the IHC Select HRP/DAB kit
(cat. DAB50, Millipore). The immunostaining was scored by pathologists in
a blinded manner. A four-tier grading system (0 = negative, 1 = weak, 2 =
moderate, and 3 = strong staining intensity) was used. The normal proximal
convoluted tubule show strong cytoplasmic staining and served as an internal
control for strong staining (score 3) (Figure 7C, normal tissue). The score of
tumor tissue was determined as compared to the staining intensity of normal
tubules on the same slide.
Statistical Analysis
Results are reported as mean ± SEM of three independent experiments.
Comparisons were performed with a two-tailed paired Student’s t test
(** p < 0.01).SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
five figures and can be found with this article online at doi:10.1016/j.cell.
2009.12.032.
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